Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICaS-monitored prevention of Hemabate adverse reactions during cesarean section
ChiCTR2000038350Phase 4Recruiting
- Sponsor
- Chongqing Health Center for Women and Children
- Start
- Oct 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sufentanil, dexmedetomidine and tramadol in adverse effect and None (4 arms), sponsored by Chongqing Health Center for Women and Children. Primary endpoints: nausea and vomiting, chest tightness and 1 more. Started Oct 2020; status: recruiting.
02
Drugs
sufentanildexmedetomidinetramadol
03
Conditions
adverse effect
Beyond the preview
Go deeper on ChiCTR2000038350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038350.